Publications by authors named "A P Tio-Gillen"
Article Synopsis
- A non-pathogenic Mycoplasma pneumoniae is being used to create live biotherapeutic products for treating respiratory diseases, but there are concerns about its connection to Guillain-Barré syndrome (GBS) after infection.
- Research identified galactolipids, particularly galactocerebroside (GalCer), as likely triggers for autoimmune responses linked to GBS, leading scientists to engineer strains without genes for galactolipid biosynthesis.
- Some modified strains showed reduced antibody recognition from GBS patients; however, other glycolipids beyond GalCer were also found to influence this recognition, prompting discussions on selecting safe Mycoplasma strains for potential therapeutic use.
Background And Objectives: Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy that may follow a preceding infection inducing a cross-reactive antibody response to glycosphingolipids in peripheral nerves. The immune response in GBS is considered to be short lasting, explaining its monophasic clinical course. However, the disease course varies between patients, and residual deficits frequently occur.
View Article and Find Full Text PDFArticle Synopsis
- Increased Fab glycosylation of autoantibodies is prevalent in chronic B cell-mediated autoimmune diseases, with varying levels found across several conditions including rheumatoid arthritis and systemic lupus erythematosus.
- Assessment methods included lectin affinity chromatography and autoantigen-specific immunoassays to determine glycosylation levels.
- The study demonstrated that chronic disease states lead to increased Fab glycosylation, while acute autoimmune diseases did not show this association, suggesting a complex relationship between autoantigen exposure and glycosylation.
Background And Objectives: Infections play a key role in the development of Guillain-Barré syndrome (GBS) and have been associated with specific clinical features and disease severity. The clinical variation of GBS across geographical regions has been suggested to be related to differences in the distribution of preceding infections, but this has not been studied on a large scale.
Methods: We analyzed the first 1,000 patients included in the International GBS Outcome Study with available biosamples (n = 768) for the presence of a recent infection with , hepatitis E virus, , cytomegalovirus, and Epstein-Barr virus.
IVIg-induced plasmablasts in patients with Guillain-Barré syndrome.
Ann Clin Transl Neurol
January 2019
Objective: The Guillain-Barré syndrome (GBS) is an acute, immune-mediated disease of peripheral nerves. Plasmablasts and plasma cells play a central role in GBS by producing neurotoxic antibodies. The standard treatment for GBS is high-dose intravenous immunoglobulins (IVIg), however the working mechanism is unknown and the response to treatment is highly variable.
View Article and Find Full Text PDF